Tuberculosis Projects at RTI: A Selection
Participating in the Global TB Alliance
As an active participant in the early development and operation of the Global Alliance for Tuberculosis Drug Development (TB Alliance), RTI has coordinated participant involvement in key elements of this public-private partnership, including
- Preparing a report on the economics of TB drug development -- working with government, university, corporate, and multilateral organizations to present a business case for involvement in TB drug development
- Managing the development of the TB Alliance's first drug candidate for improved treatment of TB
- Serving as a partner in the TB Alliance's international stakeholder association.
Supporting TB Technology Transfer
RTI is managing a project to facilitate the transfer of new anti-tuberculosis compounds into development and commercialization. To build industry interest, RTI is gathering global epidemiology and market data for new TB drugs to present a business case for investing in drug development. As promising new compounds are identified, RTI will work with the suppliers to develop comprehensive promotional packages.
To aid commercialization, RTI is facilitating partnerships among pharmaceutical companies, universities, foundations, international health and financial organizations, and the National Institutes of Health.
rti.org